MEI Pharma (MEIP) News Today $2.69 +0.04 (+1.36%) As of 02:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.comFebruary 19, 2025 | americanbankingnews.comMEI Pharma Reports Second Quarter Fiscal Year 2025 Cash PositionFebruary 12, 2025 | finance.yahoo.comMEI Pharma Registered ShsJanuary 23, 2025 | markets.businessinsider.comMEI Pharma (NASDAQ:MEIP) Stock, Option ChainNovember 18, 2024 | benzinga.comMEI Pharma Reports First Quarter Fiscal Year 2025 Cash PositionNovember 13, 2024 | finance.yahoo.comMEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 MillionOctober 25, 2024 | marketwatch.comTelix Pharmaceuticals Limited (T3X.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comMEI Pharma reviews strategic options amid fiscal changesSeptember 21, 2024 | investing.comMEI Pharma Reports Fiscal Year End 2024 Cash PositionSeptember 19, 2024 | finance.yahoo.comMEI Pharma Reports Fiscal Year End 2024 Cash PositionSeptember 19, 2024 | businesswire.comMEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic AlternativesAugust 12, 2024 | finance.yahoo.comLaidlaw & Co. Downgrades MEI Pharma (MEIP)July 24, 2024 | msn.comMEI Pharma Considering Strategic Alternatives; CEO Urso Steps DownJuly 22, 2024 | marketwatch.comMEI Pharma To Begin Evaluation Of Strategic Alternatives - Quick FactsJuly 22, 2024 | markets.businessinsider.comMEI Pharma to Consider Strategic AlternativesJuly 22, 2024 | businesswire.com7 Undervalued Biotech Stocks to Buy for Big-Time ReturnsJuly 1, 2024 | investorplace.comMEI Pharma IncMay 22, 2024 | money.usnews.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)May 14, 2024 | businesswire.comMEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024May 10, 2024 | investorplace.comMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational HighlightsMay 9, 2024 | businesswire.com5 Cheap Penny Stocks to Buy According to AnalystsApril 18, 2024 | insidermonkey.comMEI Pharma shelves plans for a second return of capitalApril 11, 2024 | msn.comMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344April 11, 2024 | businesswire.comMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsApril 11, 2024 | businesswire.comMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumApril 10, 2024 | businesswire.comMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaMarch 26, 2024 | finance.yahoo.com3 Pharma Stocks Outperforming the CompetitionMarch 20, 2024 | stocknews.comMEI Pharma Inc (MEIP)March 3, 2024 | investing.comMEIP MEI Pharma, Inc.February 29, 2024 | seekingalpha.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)February 15, 2024 | businesswire.comGlancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)February 15, 2024 | businesswire.comMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsFebruary 13, 2024 | finance.yahoo.comMEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue EstimatesFebruary 13, 2024 | finance.yahoo.comMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsFebruary 13, 2024 | businesswire.comMEI Pharma Inc.February 8, 2024 | wsj.comIs MEI Pharma (MEIP) Attractively Priced?February 8, 2024 | finance.yahoo.comAcceleron PharmaJanuary 18, 2024 | forbes.comMEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024January 16, 2024 | finance.yahoo.comMEI Pharma Stock (NASDAQ:MEIP), Short Interest ReportDecember 27, 2023 | benzinga.comMEI Pharma Stock (NASDAQ:MEIP) Dividends: History, Yield and DatesDecember 27, 2023 | benzinga.comMEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023December 11, 2023 | finance.yahoo.comStifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)November 16, 2023 | markets.businessinsider.comMEI Pharma Inc MEIPNovember 14, 2023 | morningstar.comMEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational HighlightsNovember 9, 2023 | finance.yahoo.comMEI Pharma to Present at the Stifel 2023 Healthcare ConferenceNovember 8, 2023 | finance.yahoo.comMEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common StockNovember 6, 2023 | finance.yahoo.comMEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023November 2, 2023 | finance.yahoo.comMEI Pharma Enters into Agreement with Anson Funds and Cable Car CapitalNovember 1, 2023 | finance.yahoo.comMEI Pharma Recommends Stockholders Not to ConsentOctober 17, 2023 | finance.yahoo.comAstraZeneca's (AZN) Tagrisso Combo Gets FDA's Priority ReviewOctober 17, 2023 | finance.yahoo.com Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Email Address MEIP Media Mentions By Week MEIP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MEIP News Sentiment▼0.000.55▲Average Medical News Sentiment MEIP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MEIP Articles This Week▼10▲MEIP Articles Average Week Get MEI Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aerovate Therapeutics News Genenta Science News IO Biotech News Mersana Therapeutics News Clearside Biomedical News Aadi Bioscience News BeyondSpring News Ikena Oncology News Mural Oncology News Forte Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MEIP) was last updated on 2/25/2025 by MarketBeat.com Staff From Our PartnersBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.